NBW Capital LLC Decreases Stock Position in Danaher Co. (NYSE:DHR)

NBW Capital LLC reduced its position in Danaher Co. (NYSE:DHR) by 0.2% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 24,735 shares of the conglomerate’s stock after selling 44 shares during the quarter. NBW Capital LLC’s holdings in Danaher were worth $6,180,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DHR. Tsfg LLC grew its position in shares of Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares in the last quarter. nVerses Capital LLC purchased a new stake in Danaher in the 2nd quarter valued at $25,000. CarsonAllaria Wealth Management Ltd. purchased a new position in shares of Danaher during the 2nd quarter worth $25,000. Cape Investment Advisory Inc. acquired a new position in shares of Danaher during the 4th quarter valued at about $25,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in shares of Danaher in the first quarter valued at about $30,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on DHR shares. The Goldman Sachs Group upped their price target on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Danaher in a research report on Friday, September 6th. Leerink Partners boosted their price target on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Jefferies Financial Group initiated coverage on shares of Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective for the company. Finally, Robert W. Baird upped their price target on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $278.94.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock valued at $11,042,433 in the last ninety days. Insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of Danaher stock opened at $274.73 on Wednesday. The business has a 50-day simple moving average of $268.61 and a 200-day simple moving average of $257.47. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The company has a market cap of $198.41 billion, a PE ratio of 46.56, a P/E/G ratio of 4.55 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the previous year, the business posted $2.05 EPS. The firm’s revenue was down 2.9% on a year-over-year basis. On average, equities research analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio is presently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.